【正文】 Int 2349 RESOLUTE US 1402 RESOLUTE Japan 100 5130 Resolute? ZES 入組患者 標準風(fēng)險糖尿病患者 N = 878 Matched cohort is all enrolled diabetic subjects excluding subjects with bifurcation, saphenous vein graft (SVG), ISR, AMI (≤72 hours), left ventricular ejection fraction (LVEF) 30%, an unprotected left main lesion, ≥3 vessels, renal impairment (creatinine ≥ 140181。mol/L), total lesion length per vessel 27 mm, ≥2 lesions per vessel, lesion with thrombus, or lesion with total occlusion. 所有糖尿病患者 N = 1535 標準風(fēng)險患者 FDA 適應(yīng)證 Yeung A. ACC 2020 RESOLUTE糖尿病薈萃 研究 Resolute獲得 FDA糖尿病適應(yīng)證的臨床證據(jù) * Performance goal based on DES trials metaanalysis: DIABETES, RAVEL DM, SIRIUS DM, TAXUS IV, SCORPIUS, ENDEAVOR Pooled DM. ? RESOLUTE matched cohort diabetes pooled analysis (n = 878). Windecker S. Presented at EuroPCR. 2020. Resolute 應(yīng)用于糖尿病患者，顯著降低靶血管失敗率（ TVF） TLR is ischemia driven. 所有糖尿病 患者 – 24個月臨床結(jié)果 1 3 . 41 1 . 15 . 83 . 43 . 81 . 2TLR Cardiac Death TVMI ST (ARC Def/Prob) TLF Events (%) RESOLUTE Pooled analysis, All diabetics (n=15